PubRank

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Clinical Trial ID NCT01176474

PubWeight™ 26.84‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01176474

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
2 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
3 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
4 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
5 Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1.17
6 Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res 2015 1.14
7 Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2014 1.01
8 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
9 Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014 0.89
10 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
11 Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology 2015 0.88
12 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
13 Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. Front Oncol 2014 0.85
14 Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology 2014 0.84
15 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
16 Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother 2011 0.80
17 Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014 0.75
Next 100